Clin2
NCT07109765Possibly a fitRecruiting

Secukinumab for moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa (HS)

Treatments studied

Part of Infections, Skin clinical trials.

This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
50 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years old or older.
  • You have moderate to severe hidradenitis suppurativa (HS) with tunnels under the skin or at least two painful bumps.
  • You have had HS for at least 6 months.
  • Previous treatments like antibiotics, isotretinoin, or TNF inhibitors (a type of biologic) have not worked well enough for you.
  • You do not have an active infection (like hepatitis or tuberculosis).
  • You have not used other biologic drugs or strong immune-suppressing medications in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06926192Recruiting
Secukinumab plus surgery for moderate to severe hidradenitis suppurativa

This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.

Nanjing, Jiangsu
NCT07489573Recruiting· Phase 4
Study of secukinumab for Chinese adults with moderate-to-severe HS

This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.

Guangzhou, Guangdong
NCT07261072Not yet recruiting· Phase 4
Comparing topical and injection treatment for hidradenitis suppurativa

This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.

Nanjing, Jiangsu
NCT07244510Recruiting· Phase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa

This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.

Samsun, Turkey
NCT07388446Not yet recruiting
Immune cell study in hidradenitis suppurativa

This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.

Lyon
NCT07766005Not yet recruiting· Phase 2
New medication for moderate to severe hidradenitis suppurativa

This study tests a new injected medication (SPY072) for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful bumps and abscesses. The goal is to see if this treatment can reduce symptoms and improve quality of life.

Irvine, California

Hear when a new Hidradenitis Suppurativa (HS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.